Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

BACKGROUND: Respiratory syncytial virus (RSV) is responsible for most respiratory tract infections and hospitalizations in infants and represents a significant economic burden for public health. The development of a safe, effective, and affordable vaccine is a priority for the WHO. METHODS: We condu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EClinicalMedicine
Autors principals: Abarca, Katia, Rey-Jurado, Emma, Muñoz-Durango, Natalia, Vázquez, Yaneisi, Soto, Jorge A., Gálvez, Nicolás M.S., Valdés-Ferrada, Javier, Iturriaga, Carolina, Urzúa, Marcela, Borzutzky, Arturo, Cerda, Jaime, Villarroel, Luis, Madrid, Victoria, González, Pablo A., González-Aramundiz, José V., Bueno, Susan M., Kalergis, Alexis M.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7548429/
https://ncbi.nlm.nih.gov/pubmed/33073219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100517
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars